Axogen appoints Michael Dale as CEO; Karen Zaderej steps down, remains advisory

Axogen, Inc.

Michael Dale becomes CEO, President, and Director effective August 9, 2024; Karen Zaderej exits CEO role.
Paul Thomas appointed Chair of the Board, effective August 9, 2024; he joined the Board in 2020.
Dale receives $765k base salary, 100% target bonus, and 600,000 PSUs tied to stock price goals and Avance Nerve Graft BLA approval.
Dale has 30+ years med device experience, most recently President of structural heart at Abbott (NYSE: ABT).
Zaderej remains in advisory role for nine months under a previously disclosed Transition and Separation Agreement.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Dale

Chief Executive Officer, President, and Director

AXGN · Axogen, Inc.

Effective: 2024-08-09
Filed: August 9, 2024, 7:59 PM ET

On August 8, 2024, Axogen, Inc. (the “Company”), announced the appointment of Michael Dale as its Chief Executive Officer (“CEO”) and President, effective August 9, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Dale was appointed as Chief Executive Officer, President, and Director at Axogen, Inc..

Action: appointed
Role: Chief Executive Officer, President, and Director

Exact text from the filing

On August 8, 2024, Axogen, Inc. (the “Company”), announced the appointment of Michael Dale as its Chief Executive Officer (“CEO”) and President, effective August 9, 2024 (the “Effective Date”).

View on SEC.gov

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-197821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.